Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

Gastroenterology
K D LindorE R Dickson

Abstract

Ursodeoxycholic acid (UDCA) has been shown to be a safe and effective treatment for patients with primary biliary cirrhosis; however, its effect on patient survival is less certain. To study this issue, the survival of patients receiving long-term UDCA treatment was compared with that of a control group, adjusting for their risk scores based on the Mayo model. One hundred eighty patients were randomized to receive either 13-15 mg.kg-1.day-1 UDCA (n = 89) of placebo (n = 91). After the study closure, the patients originally receiving placebo were switched to active drug, and prospective follow-up was continued for 3 years. Patients were censored at the time of transplantation, voluntary withdrawal, of crossover of the placebo group (efficacy analysis). The survival of the two groups was adjusted for risk scores at the time of entry to the study. A secondary analysis was an intent-to-treat analysis, whereby patients were followed up regardless of their voluntary withdrawal or crossover. At the time of analysis, the patients receiving placebo had a significantly increased risk of death and/or requiring transplantation (relative risk, 2.6; P = 0.04) compared with the UDCA-treated patients UDCA should be considered as a safe, effect...Continue Reading

Citations

Oct 12, 2007·The New England Journal of Medicine·Keith Lindor
Jun 26, 1998·Journal of Gastroenterology and Hepatology·K NakamuraI Makino
Jun 19, 2007·Gut·Masao OmataUNKNOWN Japanese C-Viral Hepatitis Network
Nov 21, 1998·Gut·K Cauch-DudekE J Heathcote
Mar 23, 2000·Postgraduate Medical Journal·M I Prince, D E Jones
Aug 2, 2002·Postgraduate Medical Journal·D Kumar, R K Tandon
Jan 1, 2009·Therapeutic Advances in Gastroenterology·Gideon M HirschfieldE Jenny Heathcote
Jun 6, 2008·World Journal of Gastroenterology : WJG·Andrea CrosignaniMauro Podda
Jun 13, 2009·World Journal of Gastroenterology : WJG·Shuichi SatoYoshikazu Kinoshita
Jan 3, 2014·Expert Opinion on Pharmacotherapy·Marina G Silveira, Keith D Lindor
Oct 26, 2012·Expert Opinion on Pharmacotherapy·Elizabeth J Carey, Keith D Lindor
Dec 17, 2008·Expert Review of Gastroenterology & Hepatology·Marina G Silveira, Keith D Lindor
Nov 11, 2014·Expert Review of Clinical Immunology·Ahmad H AliKeith D Lindor
Jul 1, 1999·Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·K G Benner
Aug 26, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·B CombesR L Carithers
Feb 3, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P AnguloK D Lindor
Dec 24, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T PashaK D Lindor
Jan 29, 2013·Gastroenterology·Ansgar W Lohse, Christina Weiler-Normann
Nov 16, 2011·The Journal of Pediatrics·Willemien de VriesUNKNOWN Netherlands Study Group of Biliary Atresia and Registry (NeSBAR)
Sep 21, 2010·Gastroenterology·Gideon M HirschfieldM Eric Gershwin
Jul 8, 2010·The Korean Journal of Hepatology·Byung-Cheol Song
Feb 23, 2010·Translational Research : the Journal of Laboratory and Clinical Medicine·Marina G Silveira, Keith D Lindor
May 6, 2008·Clinics in Liver Disease·Marlyn J Mayo
May 6, 2008·Clinics in Liver Disease·Marina G Silveira, Keith D Lindor
Nov 4, 2015·Alimentary Pharmacology & Therapeutics·K-A KimS-H Jeong
Sep 15, 2015·Lancet·Elizabeth J CareyKeith D Lindor
Aug 15, 2015·Cellular and Molecular Gastroenterology and Hepatology·Luca MaroniGianfranco Alpini
Jun 26, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Keith D LindorUNKNOWN American Association for Study of Liver Diseases
Apr 2, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marshall M KaplanPeter A L Bonis
Aug 24, 2006·Journal of Advanced Nursing·Roberta Jorgensen
Aug 7, 2013·Alimentary Pharmacology & Therapeutics·K M BobergI S Kristiansen
Jan 9, 2014·Hepatology Research : the Official Journal of the Japan Society of Hepatology·UNKNOWN Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis
Jan 1, 2014·Alimentary Pharmacology & Therapeutics·T H KarlsenK M Boberg
Nov 25, 2004·Clinics in Liver Disease·W R Kim, E R Dickson
Nov 25, 2004·Clinics in Liver Disease·P Angulo, K D Lindor
Apr 9, 2001·Clinics in Liver Disease·P Angulo, K D Lindor
Sep 26, 2003·Clinics in Liver Disease·Rafael Claudino Botero, Michael R Lucey
Nov 5, 2003·Clinics in Liver Disease·Robert L Carithers
May 18, 1999·The Journal of Surgical Research·F G QueG J Gores

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.